To test this idea, we asked if gene correction could limit TP53 mutational prevalence in FA tissue when TP53 mutation rates and proliferative advantages were comparable for FANC- and FANC+ cells (Figure 4CF). The gene discussed is TP53; the disease is Friedreich ataxia.